Press release
Animal Nutrition
July 9, 2012

AMINONews® – 1st Edition 2012 is now available. Evonik's customer magazine for the feed and livestock production industries

The Health & Nutrition Business Unit of Evonik Industries, Essen (Germany), has now published the latest edition of its customer magazine AMINONews® for the compound feed and livestock production industries.

In that issue our swine specialist Dr John Htoo addresses the topic "Requirements and optimum dietary branched-chain amino acids to lysine ratios for pigs".

The other two articles are:

  • "Branched-chain amino acids in broiler nutrition", by Dr Ariane Helmbrecht
  • "Roles, metabolisms and antagonisms of branched-chain amino acids in animal nutrition", by Dr John Htoo and Dr Markus Wiltafsky

Featured as "Research Highlights", the magazine also reports on current developments and latest scientific publications on amino acids for animal nutrition.

Evonik is the only company in the world that produces and markets all four essential amino acids used in advanced animal nutrition: MetAMINO® (DL-methionine), Biolys® (L-lysine), ThreAMINO® (L-threonine) and TrypAMINO® (L-tryptophan). Mepron®, a rumen-protected DL-methionine and CreAMINO® a creatine source for broilers complete the product range. The company markets innovative products and services in more than one hundred countries and thus makes a valuable contribution to the cost-efficiency of its customers and to healthy and environment-friendly animal nutrition.

Company information

Evonik, the creative industrial group from Germany, is one of the world leaders
in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2011 more than 33,000 employees generated sales of around €14.5 billion and an operating profit (adjusted EBITDA) of about €2.8 billion.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.